Verification by independent auditors ensures that a company’s financial and non-financial data is accurate. It helps in filling the gap between ESG disclosures and building investor trust.

Verdict has conducted a poll to assess whether the independent verification of ESG disclosures made by companies and businesses is important.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

A majority 83% of the respondents to the poll consider independent verification to be important, while the remaining 17% opined otherwise.

Independent verification of ESG disclosures

The analysis is based on 346 responses received from the readers of Verdict between 01 February and 16 March 2021.

Investor focus on sustainability of a business is at an all-time high and firms are making big claims about their achievements and their efforts to meet the ESG goals. The accuracy and authenticity of the ESG reports released by companies, however, might be unverified and potential investors and stakeholders are demanding authenticated information on the ESG performance of businesses.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The companies failing to comply with the investors’ requests for a verified ESG disclosure are also being accused of resorting to greenwashing and reporting distorted facts. The problem can be resolved by applying suitable regulatory tools such as compulsory audit of sustainability data through independent auditors for their accuracy. This will enable companies to identify drawbacks in their reporting mechanism and ESG fundamental data, while helping them improve the implementation of ESG programmes.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact